

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE: Application of Bryan James GOODWIN et al.

Serial No.: To be assigned

Art Unit: To be assigned

Filing Date: Concurrently herewith

Examiner: To be assigned

For: *LHR1 Activators as Medicaments*

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_  
(37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_  
PCT/US2005/005754 is submitted herewith. All of the publications cited in the  
International Search Report are listed on the attached form PTO-1449 and Applicants  
understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
  - (2) a notice of allowance under § 1.311,
- whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

/Michael M. Conger/  
Michael M. Conger  
Attorney of Record  
Registration No. 43,562

Date: August 24, 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-2474  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>SERIAL NO.</b>	<b>To be assigned</b>		
				<b>FILING DATE</b>	<b>Concurrently herewith</b>		
				<b>APPLICANT</b>	<b>Bryan James GOODWIN, et al.</b>		
				<b>GROUP</b>	<b>To be assigned</b>		
				<b>EXAMINER</b>	<b>To be assigned</b>		
				<b>ATTORNEY DOCKET NO.</b>	<b>PR60742USw</b>		
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
Continue on page _____							
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
Continue on page _____							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	1.	Davis et al., "Convergent synthesis of aminobicyclo[3.3.0]octenes using zirconium chemistry an unusual anti-1,3-amine shift," <i>Synlett, Thieme Verlag, Stuttgart, DE (2)</i> :110-112 (Feb. 1994)					
	2.	Fayard et al., "Liver receptor homolog 1 controls the expression of carboxyl ester lipase," <i>Journal of Biological Chemistry</i> <b>278(37)</b> :35725-35731 (Sep. 2003)					
Continue on page _____							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							